A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
BACKGROUND: The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid leukemia (AML). Few non-clinical studies have directly compared the mechanisms of action of these agents in a head-to-head fashio...
Main Authors: | Paul W Hollenbach, Aaron N Nguyen, Helen Brady, Michelle Williams, Yuhong Ning, Normand Richard, Leslie Krushel, Sharon L Aukerman, Carla Heise, Kyle J MacBeth |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2814859?pdf=render |
Similar Items
-
Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
by: Bingbing Wen, et al.
Published: (2020-03-01) -
Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
by: Jiale Ma, et al.
Published: (2021-08-01) -
Decitabine in the treatment of acute myeloid leukemia in elderly patients
by: Malik P, et al.
Published: (2014-02-01) -
Decitabine for Acute Myeloid Leukemia in a Patient Undergoing Hemodialysis
by: T.V. Kourelis, et al.
Published: (2011-09-01) -
The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
by: Shi M, et al.
Published: (2019-09-01)